EP102 Safety and Efficacy in METTL3 Modulation in Advanced Solid Tumors

Summary

This the first-in-human (FIH) study for the Investigational Medicinal Product (IMP) EP102, is designed to explore the maximum tolerated dose (MTD), the overall safety profile, its pharmacokinetic (PK) / pharmacodynamic (PD) profile, and an exploratory evaluation of antitumor activity in participants with advanced solid tumors, who have no available standard therapy or who have failed standard therapies. This study will inform on recommended doses for further studies, e.g. dose optimization studies and / or efficacy and safety studies.

Timeline

Start

2025-07-24

Primary completion

2027-11

Completion

2028-11

Publications

• Background Dutheuil G, Oukoloff K, Korac J, Lenoir F, El Bousmaqui M, Probst N, Lapin A, Nakhabina G, Sorlet C, Parmentier N, Karila D, Ghavtadze N, Casault P, Claridge S, Sapmaz S, Slater MJ, Fraser GL. Discovery, Optimization, and Preclinical Pharmacology of EP652, a METTL3 Inhibitor with Efficacy in Liquid and Solid Tumor Models. J Med Chem. 2025 Feb 13;68(3):2981-3003. doi: 10.1021/acs.jmedchem.4c02225. Epub 2025 Jan 30.
• Abbad L, Chatziantoniou C. Discovering New Therapies for Kidney Fibrosis: The Promise of Epigenetic and Epitranscriptomic Modulation. J Am Soc Nephrol. 2026 Jul 1;37(7):1367-1369. doi: 10.1681/ASN.0000001136. Epub 2026 May 28. No abstract available.

Drugs

Indications

No indication recorded.